Triple Negative Clinical Trial Abraxane Gemzar Carboplatin

prnciss74

I had previously posted in the "Calling all TNS" but figured I would start a new post. Hope that is ok. 

Checking in here. I am a long time lurker! Just diagnosed at age 39 with metastatic breast cancer to axillary lymph node. It started with cellulitis and an infection in my under arm and left breast area late January into February. I had been feeling fullness in my arm and it felt heavy. I thought it was maybe lymphedema. Went to see my primary and he ordered an MRI and they requested core needle biopsy of the area. Same side as the original breast cancer. I had previously underwent bilateral mastectomy because I did not want to have to worry about my right breast in the future. I completed my chemo treatment of TAC and had a prophylactic hysterectomy because of my BRCA2 status.

Met with my new onc. Thursday 3/6/14 and she wants to start me on chemo next Thursday 3/13/14 the day before my 40th birthday. She immediately ordered CT, bones scan, port insertion and I will have an EKG. I'm going to be part of a clinical trial here in San Antonio at the Cancer Care Center of South Texas for Triple Negatives. Everything is going so fast. Below is the info:

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC). In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in triple negative metastatic breast cancer (TNMBC) subjects.

I would love to hear from anyone taking part in the study. I will know next week what I will be taking.